89985-87-5Relevant articles and documents
Silole Amino Acids with Aggregation-Induced Emission Features Synthesized by Hydrosilylation
Arribat, Mathieu,Rémond, Emmanuelle,Richeter, Sébastien,Gerbier, Philippe,Clément, Sébastien,Cavelier, Florine
, p. 2275 - 2281 (2019)
The synthesis of silole amino acids was achieved through hydrosilylation of alkene or alkyne-containing amino acids with 1-methyl-2,3,4,5-tetraphenyl-1H-silole, using Karstedt's catalyst with yield up to 95 % and without epimerization. After selective deprotection of carboxylic acid or amine functions respectively, C- or N-peptide coupling with an alanine moiety proved their possible incorporation into peptides. A model tripeptide was synthesized by solid phase synthesis with the N-Fmoc protected silole amino acid version. The silole moiety can be also grafted on a precursor peptide directly on the solid support. These amino acids and peptides exhibit AIE properties with λem ca. 500 nm and Δλ ca. 100 nm. This approach constitutes an alternative and promising strategy for incorporation of such AIE fluorogens to peptides.
Microelectrode Arrays, Dihydroxylation, and the Development of an Orthogonal Safety-Catch Linker
Yeh, Nai-Hua,Krueger, Ruby,Moeller, Kevin D.
, p. 5440 - 5444 (2021/07/26)
Construction of larger molecular libraries on an addressable microelectrode array requires a method for recovering and characterizing molecules from the surface of any electrode in the array. This method must be orthogonal to the synthetic strategies needed to build the array. We report here a method for achieving this goal that employs the site-selective dihydroxylation reaction of a simple olefin.
PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF
-
Paragraph 00836, (2020/09/27)
Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders and conditions favorably responsive to PTPN 1 or PTPN2 inhibitor treatment, e.g., a cancer or a metabolic disease.